Fda Vaccine Approval

• The U.S. FDA has approved a supplemental Biologics License Application for Pfizer and BioNTech’s 2026-2027 COVID-19 vaccine formula. • The updated vaccine, COMIRNATY ® XFG, specifically targets the XFG variant to better align with currently circulating strains of the virus. • Approval is granted for adults aged 65 and older, as well as individuals aged 5 to 64 who have underlying conditions increasing their risk of severe illness.

• The FDA has approved the first-of-its-kind mRNA-based flu vaccine specifically for adults aged 50 and older. • This approval follows a severe 2024-25 flu season, which the CDC estimates resulted in approximately 45,000 deaths. • The shift to mRNA technology is significant as it offers the potential for more effective, rapidly adaptable vaccines compared to traditional methods.

• The FDA has granted approval for a new narcolepsy medication developed by Takeda Pharmaceutical. • In a significant medical milestone, the first-ever mRNA-based influenza vaccine has also received FDA approval. • These approvals highlight the expanding utility of mRNA technology beyond COVID-19 and provide new treatment options for sleep disorders.